The immune response during acute HIV-1 infection: clues for vaccine development

McMichael, Andrew J.; Borrow, Persephone; Tomaras, Georgia D.; Goonetilleke, Nilu; Haynes, Barton F.
January 2010
Nature Reviews Immunology;Jan2010, Vol. 10 Issue 1, p11
Academic Journal
journal article
The early immune response to HIV-1 infection is likely to be an important factor in determining the clinical course of disease. Recent data indicate that the HIV-1 quasispecies that arise following a mucosal infection are usually derived from a single transmitted virus. Moreover, the finding that the first effective immune responses drive the selection of virus escape mutations provides insight into the earliest immune responses against the transmitted virus and their contributions to the control of acute viraemia. Strong innate and adaptive immune responses occur subsequently but they are too late to eliminate the infection. In this Review, we discuss recent studies on the kinetics and quality of early immune responses to HIV-1 and their implications for developing a successful preventive HIV-1 vaccine.


Related Articles

  • Development of Core-Corona Type Polymeric Nanoparticles as an Anti-HIV-1 Vaccine. Wang, Xin; Akagi, Takami; Akashi, Mitsuru; Baba, Masanori // Mini-Reviews in Organic Chemistry;Feb2007, Vol. 4 Issue 1, p51 

    We developed a novel technology for core-corona polymeric nanoparticles having hydrophilic polymer chains with functional groups. Polystyrene nanoparticles immobilized with the mannose-specific lectin concanavalin A could efficiently capture human immunodeficiency virus type 1 (HIV-1) particles...

  • The Role of Mucosal Immunity in Prevention of HIV Transmission. Kozlowski, Pamela A.; Neutra, Marian R. // Current Molecular Medicine;May2003, Vol. 3 Issue 3, p217 

    Vaccines designed to prevent mucosal transmission of HIV should establish multiple immune effectors in vaccine recipients, including antibodies which are capable of blocking HIV entry at mucosal epithelial barriers and of preventing initial infection of target cells in the mucosa. Immunological...

  • First candidate HIV vaccine to employ Sendai vector poised for trials. McEnery, Regina // VAX;Mar2013, Vol. 11 Issue 2, p3 

    The article presents information on Sendai virus, an RNA virus that is being used as a viral vector in an AIDS vaccine trial. The vector carries an immunogen from HIV virus; and the vector can replicate within the body after delivery. Researchers hope that the Sendai candidate might result in...

  • The aftermath of the Merck's HIV vaccine trial. Iaccino, Enrico; Schiavone, Marco; Fiume, Giuseppe; Quinto, Ileana; Scala, Giuseppe // Retrovirology;2008, Vol. 5, Special section p1 

    The recently released results of the Merck's Phase IIb "test-of concept" vaccine trials have shown no protection from HIV-1 infection in the vaccinated group compared with a control group vaccinated with placebo. The study was designed to test the Merck's MRKAd5 trivalent candidate vaccine. The...

  • HIV vaccine design: insights from live attenuated SIV vaccines. Koff, Wayne C.; Johnson, Philip R.; Watkins, David I.; Burton, Dennis R.; Lifson, Jeffrey D.; Hasenkrug, Kim J.; McDermott, Adrian B.; Schultz, Alan; Zamb, Timothy J.; Boyle, Rosanne; Desrosiers, Ronald C. // Nature Immunology;Jan2006, Vol. 7 Issue 1, p19 

    The International AIDS Vaccine Initiative has established a consortium to elucidate mechanisms of protection conferred by live attenuated simian immunodeficiency virus vaccines in monkeys. Here, the strategies defining key components of the protective immune response elicited by these vaccines...

  • Editorial [Hot Topic: HIV Vaccine Discovery and Development (Guest Editor: Julia L. Hurwitz)]. Hurwitz, Julia L. // Current Drug Targets - Infectious Disorders;Jun2005, Vol. 5 Issue 2, p81 

    Examines the fundamental concepts of immunology as they relate to the development of HIV vaccine. Assessment on the magnitude of human misery caused by the HIV pandemic; Investigation on the protective potentials of neutralizing antibodies and T-cell populations; Development of novel vaccine...

  • New Approaches in the Potential Treatment of HIV–acquired Immunodeficiency Disease. Williams, David A // Molecular Therapy;Feb2009, Vol. 17 Issue 2, p209 

    The article presents a study on the potential treatment of HIV and AIDS. With this, several new studies report progress in the further development of approaches to manipulating the immune response to HIV. They are hoping to delay or prevent the loss of immune function leading to AIDS. A result...

  • Induction of Optimal Immune Responses Against Human Immunodeficiency Virus at Mucosal Portals of Entry. Vajdy, M. // Current Drug Targets - Immune, Endocrine & Metabolic Disorders;Sep2003, Vol. 3 Issue 3, p222 

    Mucosal surfaces comprise the largest surface area of the human body and are the first line of defense against many pathogens. In fact, over 90% of common infectious disease pathogens in humans gain access to the host through mucosal membranes. A number of studies have demonstrated that mucosal...

  • Human immune response may be pivotal for future HIV vaccines. Volansky, Rob // Infectious Disease News;Oct2008, Vol. 21 Issue 10, p35 

    The article discusses research being done on the link between human immune response and human immunodeficiency virus (HIV) vaccines. It references a study Alan Bernstein, presented at the XVII International AIDS Conference held in August 2008. Bernstein claimed that the interactions between...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics